{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059522","form_type":"8-K","ticker":null,"cik":"0001661460","company_name":"Poseida Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.480546+00:00","generated_at":"2026-06-02T00:56:54.179866+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Poseida Q1 rev $28.1M, net loss $24.3M; Astellas $50M upfront collab, new CMO","bullets":["Revenue $28.1M vs $10.3M YoY; net loss $24.3M vs $38.8M; cash $198.6M, runway into H2 2025.","Astellas research collaboration: $50M upfront, up to $550M milestones, low double-digit royalties for solid tumor CAR-T.","Roche partnership: $30M milestone in Q1, $15M expected May 2024; total $95M in 2024 milestones/upfront.","P-BCMA-ALLO1 data: 60% overall response rate in RRMM patients after prior BCMA-directed therapy.","Appointed Syed Rizvi, M.D., as Chief Medical Officer in April 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059522","json":"https://secwatch.observer/filing/0000950170-24-059522.json","markdown":"https://secwatch.observer/filing/0000950170-24-059522.md","text":"https://secwatch.observer/filing/0000950170-24-059522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024059522/0000950170-24-059522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024059522/pstx-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:56:54.179866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"afe002851884779139081388d6dde46131bb84f0","claim":"Poseida Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Poseida Therapeutics, Inc. (the “Company”) issued a press release announcing its updates and financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024059522/0000950170-24-059522-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}